Champions Oncology Inc (CSBR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.72-0.84%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Champions Oncology Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-10-31
Revenue	—	16.37M
EPS	—	0.02
Annual ending 2027-04-30
Revenue	—	65.26M
EPS	—	0.1
Annual ending 2028-04-30
Revenue	—	70.81M
EPS	—	0

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve positive adjusted EBITDA for fiscal year	Champions Oncology aims to reach positive adjusted EBITDA this fiscal year.	Intact	adjusted EBITDA remains negative through FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable CEO leadership	The new CEO hired in 2025 brings stable leadership.	Intact	CEO departs within 12 months	CEO stable vs no departure target News and events show no CEO departure. A director resigned in March 2026, but CEO leadership remains intact. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize revenue near $65 million	Revenue is expected near $65 million next year.	Intact	revenue falls below $60 million next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain valuation discount to peers	A supporting condition in Champions Oncology Inc's published investment case. The stated target is EV/EBITDA <= 15 and FCF yield >= 5%.	Intact	EV/EBITDA rises above 20 or FCF yield falls below 3%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-04-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	0 / 1
2026-07-25	Unavailable	Unavailable	0 / 1
2026-07-26	Unavailable	Unavailable	0 / 1
2026-07-27	Unavailable	Unavailable	0 / 1
2026-07-28	Unavailable	Unavailable	0 / 1
2026-07-29	Unavailable	Unavailable	0 / 1
2026-07-30	Unavailable	Unavailable	0 / 1
2026-07-31	Unavailable	Unavailable	0 / 1
2026-08-01	Unavailable	Unavailable	0 / 1
2026-08-02	Unavailable	Unavailable	0 / 1
2026-08-03	Unavailable	Unavailable	0 / 1
2026-08-04	Unavailable	Unavailable	0 / 1
2026-08-05	Unavailable	Unavailable	0 / 1
2026-08-06	Unavailable	Unavailable	0 / 1
2026-08-07	Unavailable	Unavailable	0 / 1
2026-08-08	Unavailable	Unavailable	0 / 1
2026-08-09	Unavailable	Unavailable	0 / 1
2026-08-10	Unavailable	Unavailable	0 / 1
2026-08-11	Unavailable	Unavailable	0 / 1
2026-08-12	Unavailable	Unavailable	0 / 1
2026-08-13	Unavailable	Unavailable	0 / 1
2026-08-14	Unavailable	Unavailable	0 / 1
2026-08-15	Unavailable	Unavailable	0 / 1
2026-08-16	Unavailable	Unavailable	0 / 1
2026-08-17	Unavailable	Unavailable	0 / 1
2026-08-18	Unavailable	Unavailable	0 / 1
2026-08-19	Unavailable	Unavailable	0 / 1
2026-08-20	Unavailable	Unavailable	0 / 1
2026-08-21	Unavailable	Unavailable	0 / 1
2026-08-22	Unavailable	Unavailable	0 / 1
2026-08-23	Unavailable	Unavailable	0 / 1
2026-08-24	Unavailable	Unavailable	0 / 1
2026-08-25	Unavailable	Unavailable	0 / 1
2026-08-26	Unavailable	Unavailable	0 / 1
2026-08-27	Unavailable	Unavailable	0 / 1
2026-08-28	Unavailable	Unavailable	0 / 1
2026-08-29	Unavailable	Unavailable	0 / 1
2026-08-30	Unavailable	Unavailable	0 / 1
2026-08-31	Unavailable	Unavailable	0 / 1
2026-09-01	Unavailable	Unavailable	0 / 1
2026-09-02	Unavailable	Unavailable	0 / 1
2026-09-03	Unavailable	Unavailable	0 / 1
2026-09-04	Unavailable	Unavailable	0 / 1
2026-09-05	Unavailable	Unavailable	0 / 1
2026-09-06	Unavailable	Unavailable	0 / 1
2026-09-07	Unavailable	Unavailable	0 / 1
2026-09-08	Unavailable	Unavailable	0 / 1
2026-09-09	Unavailable	Unavailable	0 / 1
2026-09-10	Unavailable	Unavailable	0 / 1
2026-09-11	Unavailable	Unavailable	0 / 1
2026-09-12	Unavailable	Unavailable	0 / 1
2026-09-13	Unavailable	Unavailable	0 / 1
2026-09-14	Unavailable	Unavailable	0 / 1
2026-09-15	Unavailable	Unavailable	0 / 1
2026-09-16	Unavailable	Unavailable	0 / 1
2026-09-17	Unavailable	Unavailable	0 / 1
2026-09-18	Unavailable	Unavailable	0 / 1
2026-09-19	Unavailable	Unavailable	0 / 1
2026-09-20	Unavailable	Unavailable	0 / 1
2026-09-21	Unavailable	Unavailable	0 / 1
2026-09-22	Unavailable	Unavailable	0 / 1
2026-09-23	Unavailable	Unavailable	0 / 1
2026-09-24	Unavailable	Unavailable	0 / 1
2026-09-25	Unavailable	Unavailable	0 / 1
2026-09-26	Unavailable	Unavailable	0 / 1
2026-09-27	Unavailable	Unavailable	0 / 1
2026-09-28	Unavailable	Unavailable	0 / 1
2026-09-29	Unavailable	Unavailable	0 / 1
2026-09-30	Unavailable	Unavailable	0 / 1
2026-10-01	Unavailable	Unavailable	0 / 1
2026-10-02	Unavailable	Unavailable	0 / 1
2026-10-03	Unavailable	Unavailable	0 / 1
2026-10-04	Unavailable	Unavailable	0 / 1
2026-10-05	Unavailable	Unavailable	0 / 1
2026-10-06	Unavailable	Unavailable	0 / 1
2026-10-07	Unavailable	Unavailable	0 / 1
2026-10-08	Unavailable	Unavailable	0 / 1
2026-10-09	Unavailable	Unavailable	0 / 1
2026-10-10	Unavailable	Unavailable	0 / 1
2026-10-11	Unavailable	Unavailable	0 / 1
2026-10-12	Unavailable	Unavailable	0 / 1
2026-10-13	Unavailable	Unavailable	0 / 1
2026-10-14	Unavailable	Unavailable	0 / 1
2026-10-15	Unavailable	Unavailable	0 / 1
2026-10-16	Unavailable	Unavailable	0 / 1
2026-10-17	Unavailable	Unavailable	0 / 1
2026-10-18	Unavailable	Unavailable	0 / 1
2026-10-19	Unavailable	Unavailable	0 / 1
2026-10-20	Unavailable	Unavailable	0 / 1
2026-10-21	Unavailable	Unavailable	0 / 1
2026-10-22	Unavailable	Unavailable	0 / 1
2026-10-23	Unavailable	Unavailable	0 / 1
2026-10-24	Unavailable	Unavailable	0 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Monthly analyst history is unavailable.

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve positive adjusted EBITDA for fiscal yearDirect metric needs a verified mapping
Stabilize revenue near $65 millionDirect metric needs a verified mapping
Maintain valuation discount to peersDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-39.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Champions Oncology Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, small-cap growth story rather than a proven durable compounder, with losses and weak recent financial performance. The multi-year view is mixed: revenue has grown, but adjusted EBITDA has fallen from the prior year and the latest earnings event was negative.

What's priced into Champions Oncology Inc

CSBR is described as cheap versus peers, while the valuation model has low confidence and shows a negative expectations gap. Pricing is tagged as justified, with no fragility gates fired, but the evidence does not show that the valuation discount alone resolves the business risks.

What the fundamentals likely do

Near term, revenue growth has continued and management is pursuing data and radiopharmaceutical investments, while positive adjusted EBITDA has been maintained but at a lower full-year level. An earnings miss was reported in September, and the next-quarter miss risk is elevated; a guidance cut or further weakening in jobs could add pressure to the operating outlook.

What Champions Oncology Inc hinges on

The multi-year thesis hinges on revenue growth continuing and investments in proprietary data and radiopharmaceutical capabilities supporting the business over time. Near term, guidance and earnings execution are key swing factors; weaker jobs could weigh on cyclical healthcare names, while strong results and guidance from sector bellwethers could support the sector backdrop.